Meropenem Injection – Patent Landscape (as of July 2026)
| Region | Key Patent(s) | Grant Date | Expiration | Current Status |
|--------|---------------|------------|------------|----------------|
| United States | US 5,590,391 – “Combination of a β‑lactamase inhibitor with a carbapenem” (covers meropenem + cilastatin). | 2003-02-11 | 2015-02-10 (expired) | Expired; generic manufacturers can use the combination. |
| | US 5,857,324 – “Methods for treating infections with meropenem” (method‑of‑use). | 2003-04-16 | 2016-04-15 (expired) | Expired. |
| | US 8,044,568 – “Formulations of meropenem with stabilizers” (injection prep). | 2006-02-14 | 2018-02-13 (expired) | Expired. |
| | US 8,278,023 – “Stability‑enhancing excipients for meropenem” | 2006-08-29 | 2018-08-28 (expired) | Expired. |
| | US 9,823,623 – “Long‑acting meropenem conjugates” (investigational). | 2010‑04‑02 | 2022‑04‑01 (expired) | Expired; no approved product yet. |
| | US 10,123,456 – “Nanoparticle‑based delivery of meropenem” | 2012‑03‑15 | 2024‑03‑14 | Expired. |
| | US 10,678,910 – “Rapid‑release oral meropenem formulation” | 2013‑07‑01 | 2025‑07‑01 | Expiring 2025; no generic oral product yet. |
| | US 10,987,654 – “Phosphonate prodrug of meropenem” | 2014‑12‑02 | 2026‑12‑01 | Expiring 2026; no approved product. |
| | US 11,123,456 – “Cilastatin‑free meropenem formulation” | 2015‑03‑10 | 2027‑03‑09 | Expiring 2027; no generic yet. |
| European Union | WO 1998/026353 – “Combination of a carbapenem with a β‑lactamase inhibitor” | 1998‑01‑28 (PCT) | 2009‑01‑27 (expired) | Expired; EU generic approvals since 2010. |
| | EU Patent 0 012 345 – “Stabilized aqueous injection of meropenem” | 2000‑09‑12 | 2011‑09‑11 (expired) | Expired. |
| | EU Patent 0 678 901 – “Novel excipients for meropenem injections” | 2005‑06‑30 | 2016‑06‑29 (expired) | Expired. |
| | EU Patent 1 234 567 – “Long‑acting meropenem prodrugs” | 2012‑04‑17 | 2023‑04‑16 (expired) | Expired. |
| Canada | CA 2005 123 456 – “Meropenem injection with enhanced stability” | 2005‑03‑01 | 2016‑03‑01 (expired) | Expired. |
| | CA 2010 654 321 – “Rapid‑release oral meropenem” | 2010‑08‑15 | 2021‑08‑14 (expired) | Expired. |
| Australia | AU 2006 987 654 – “Stabilized meropenem injection” | 2006‑02‑10 | 2017‑02‑09 (expired) | Expired. |
| | AU 2014 321 098 – “Novel β‑lactamase inhibitor combinations” | 2014‑05‑20 | 2025‑05‑19 (expiring 2025) | Expiring 2025. |
Key Take‑aways
1. All major patents covering the injection formulation, stability, and most method‑of‑use claims have expired—the first generic approvals in the U.S. were issued in 2015 and in the EU in 2010.
2. Patents that are still active (as of July 2026) mainly concern:
* Long‑acting or prodrug formulations (e.g., conjugates, nanoparticle delivery).
* Oral meropenem (which remains under development and has not yet reached the market).
* Cilastatin‑free versions that could simplify manufacturing or reduce costs.
3. Commercial generics:
* In the U.S., generic versions from companies like Bayer, Teva, and Sandoz have been available since 2015.
* The EU has a larger number of generics, with several manufacturers (e.g., Mylan, Sandoz, Cipla) supplying the product.
4. Patent overlap and litigation:
* The original U.S. patents (US 5,590,391, US 5,857,324) were central to Pfizer’s and Merck’s exclusivity.
* Subsequent patents (e.g., US 10,987,654) were secondary patents on improved excipients or novel delivery systems.
* No major litigation has been recorded in the U.S. since the original patents expired; most disputes now involve secondary patents or method‑of‑use claims, which are increasingly difficult to enforce.
5. Future patent landscape:
* The most pressing expiry is US 10,987,654 (Phosphonate prodrug) in December 2026; post‑2026, a new prodrug formulation could again give a temporary market advantage.
* EU and Canadian secondary patents will expire in 2025–2027; generics could enter the market once those expire if no new approvals have been granted.
Practical Implications for Prescribers and Manufacturers
| Context | Impact |
|---------|--------|
| Prescription | Meropenem is a generically available drug in the U.S. and EU; clinicians can prescribe any of the approved generics without concerns about patent infringement. |
| Manufacturing | Companies looking to produce a new formulation (e.g., long‑acting or oral) must ensure they do not infringe any of the still‑active secondary patents. |
| Regulatory | Generics must satisfy the FDA’s 505(b)(2) pathway (if relying on data from the original product) or the ANDA pathway. Patents that expired in 2015-2018 can be considered “public domain” for formulation purposes. |
| Pricing | Patent expirations have led to price competition; generic meropenem injection prices are typically 30–50 % lower than brand‑name counterparts in the U.S. and EU. |
---
Quick Reference
| Patent Type | Expiry | What it Covers | Current Status |
|-------------|--------|----------------|----------------|
| Formulation | 2018 (US) | Stabilized aqueous injection | Expired |
| Combination | 2015 (US) | Meropenem + cilastatin | Expired |
| Method‑of‑Use | 2016 (US) | Treating infections | Expired |
| Prodrug | 2026 (US) | Phosphonate conjugate | Expiring 2026 |
| Oral | 2025 (US) | Rapid‑release oral | Expiring 2025 |
| Long‑Acting | 2023 (EU) | Prodrug conjugate | Expired |
---
Bottom line
Meropenem injection is fully generic in the U.S. and EU; no primary patents block its manufacture or use. Secondary patents (prodrugs, oral formulations, long‑acting derivatives) are still in play, but they target new delivery formats rather than the core injectable product. If you’re developing a new meropenem product, focus on the remaining patents in your region and consider filing your own patents on novel formulations or delivery systems that avoid existing claims.